Pediatric Oncology | Specialty

ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL

July 12th 2017

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

FDA Grants Dasatinib Priority Review for Children With Ph+ Chronic Phase CML

July 11th 2017

The FDA has accepted a supplemental new drug application for dasatinib (Sprycel) for use in children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML).

CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL

June 25th 2017

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.

Making Strides Against a Rare Disease: Renal Medullary Carcinoma in Focus

June 8th 2017

Renal medullary carcinoma is a rare but devastating tumor type almost exclusively affecting young adults carrying 1 copy of hemoglobin beta (HBB) harboring the A17T mutation (HbS).

Late Effects of Childhood Cancers Dropping Along With Intensity of Treatments

June 3rd 2017

The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.

Uridine Triacetate for 5-FU or Capecitabine Toxicity

May 30th 2017

Emergency Management of Chemotherapy Toxicity

May 30th 2017

Severe Early-Onset Toxicities From 5-FU or Capecitabine

May 30th 2017

5-FU or Capecitabine Toxicity Patient Education

May 30th 2017

Chemotherapy Overdose of 5-FU or Capecitabine

May 30th 2017

Nursing Perspective of Early-Onset Severe Toxicities

May 30th 2017

Early-Onset Toxicities from 5-FU and Capecitabine

May 30th 2017

Chemotherapy for Metastatic Colorectal Cancer in 2017

May 30th 2017

Dr. Roth on Treating AYA Patients With Hodgkin Lymphoma

May 10th 2017

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma

April 17th 2017

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

Dr. Gordon on Next Steps With Immunotherapy Research in Osteosarcoma

March 15th 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

January 21st 2017

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Preclinical Activity With Olaratumab in Sarcoma

January 6th 2017

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated

December 4th 2016

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL

December 4th 2016

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.